RESEARCH TRIANGLE PARK – Catalent is buying Greenville-based contract development and manufacturing organization (CDMO) Metrics Contract Services.
The deal is worth $475 million according to Catalent, which specializes in drug development, delivery and manufacturing, biologics, gene therapies and consumer health products. The company said the acquisition will strengthen its oral solid formulation development, manufacturing and packaging and expand its ability to handle high-potency compounds.
Metrics Contract Services, which is owned by Mayne Pharma Group Limited of Australia, operates a 333,000-square-foot facility in Greenville. It includes 16 manufacturing suites, with 11 that can handle high-potency compounds, as well as two packaging lines to support a variety of development and commercial supply programs.
The facility’s estimated annual production capacity exceeds one billion oral solid dose units. Catalent said the site has invested more than $100 million in capital improvements over the past five years.
Metrics was founded as a contract analytical laboratory in 1994 by Phil Hodges, a scientist at the pharmaceutical company Burroughs Wellcome in Research Triangle Park, and East Carolina University professor John Bray. Mayne Pharma acquired it in 2012.
Aris Gennadios, Ph.D., group president of Catalent’s Pharma & Consumer Health segment, said the acquisition “will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. This capacity is particularly important for customers with R&D pipelines featuring accelerated orphan and rare disease programs for oncology and other important therapeutic areas,” he added.
Catalent said it will integrate the Greenville facility into its oral development and manufacturing network, which includes sites for large-scale and controlled release oral solids manufacturing in Winchester, Kentucky and softgel development and manufacturing in St. Petersburg, Florida.
Metrics’ 400 Greenville employees will join Catalent when the acquisition closes, most likely before the end of this year. Catalent will continue to manufacture Mayne products under a long-term supply agreement.
“Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid dose CDMO,” said Mayne Pharma CEO Scott Richards. “Catalent, a global leader in advanced drug development manufacturing, is well positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers.”
Catalent is an S&P 500 company with more than 50 global sites that supply over 70 billion doses of nearly 7,000 products annually. The company is headquartered in Somerset, New Jersey and has a workforce of approximately 19,000. It generated $4 billion in annual sales in 2021.
(C) N.C. Biotech Center